Show simple item record

dc.contributor.authorBourgeois, Florence T.
dc.contributor.authorMurthy, Srinivas
dc.contributor.authorMandl, Kenneth D.
dc.date.accessioned2012-06-27T21:06:29Z
dc.date.available2012-06-27T21:06:29Z
dc.date.issued2012-01
dc.date.submitted2011-10
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/1721.1/71236
dc.description.abstractBackground The $1.1 billion investment in comparative effectiveness research will reshape the evidence-base supporting decisions about treatment effectiveness, safety, and cost. Defining the current prevalence and characteristics of comparative effectiveness (CE) research will enable future assessments of the impact of this program. Methods We conducted an observational study of clinical trials addressing priority research topics defined by the Institute of Medicine and conducted in the US between 2007 and 2010. Trials were identified in ClinicalTrials.gov. Main outcome measures were the prevalence of comparative effectiveness research, nature of comparators selected, funding sources, and impact of these factors on results. Results 231 (22.3%; 95% CI 19.8%–24.9%) studies were CE studies and 804 (77.7%; 95% CI, 75.1%–80.2%) were non-CE studies, with 379 (36.6%; 95% CI, 33.7%–39.6%) employing a placebo control and 425 (41.1%; 95% CI, 38.1%–44.1%) no control. The most common treatments examined in CE studies were drug interventions (37.2%), behavioral interventions (28.6%), and procedures (15.6%). Study findings were favorable for the experimental treatment in 34.8% of CE studies and greater than twice as many (78.6%) non-CE studies (P<0.001). CE studies were more likely to receive government funding (P = 0.003) and less likely to receive industry funding (P = 0.01), with 71.8% of CE studies primarily funded by a noncommercial source. The types of interventions studied differed based on funding source, with 95.4% of industry trials studying a drug or device. In addition, industry-funded CE studies were associated with the fewest pediatric subjects (P<0.001), the largest anticipated sample size (P<0.001), and the shortest study duration (P<0.001). Conclusions In this sample of studies examining high priority areas for CE research, less than a quarter are CE studies and the majority is supported by government and nonprofits. The low prevalence of CE research exists across CE studies with a broad array of interventions and characteristics.en_US
dc.description.sponsorshipNational Library of Medicine (U.S.) (5G08LM009778)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.)en_US
dc.language.isoen_US
dc.publisherPublic Library of Scienceen_US
dc.relation.isversionofhttp://dx.doi.org/10.1371/journal.pone.0028820en_US
dc.rightsCreative Commons Attributionen_US
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/en_US
dc.sourcePLoSen_US
dc.titleComparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.goven_US
dc.typeArticleen_US
dc.identifier.citationBourgeois, Florence T., Srinivas Murthy, and Kenneth D. Mandl. “Comparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.gov.” Ed. Laxmaiah Manchikanti. PLoS ONE 7.1 (2012): e28820. Web. 27 June 2012.en_US
dc.contributor.departmentHarvard University--MIT Division of Health Sciences and Technologyen_US
dc.contributor.approverMandl, Kenneth D.
dc.contributor.mitauthorMandl, Kenneth D.
dc.relation.journalPLoS ONEen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsBourgeois, Florence T.; Murthy, Srinivas; Mandl, Kenneth D.en
mit.licensePUBLISHER_CCen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record